Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2

  1. Theocharis G. Konstantinidis
  2. Stavroula Zisaki
  3. Ioannis Mitroulis
  4. Eleni Konstantinidou
  5. Eftychia G. Kontekaki
  6. Gioulia Romanidou
  7. Alexandros Karvelas
  8. Ioanna Nanousi
  9. Leonidas Lazidis
  10. Dimitrios Cassimos
  11. Christina Tsigalou
  12. Georges Martinis
  13. Maria Panopoulou

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

The aim of this study was to estimate the immunogenic effect of mRNA vaccine against SARS-CoV-2. This study included 510 participants who received mRNA vaccine. The measurement of anti-COVID-19 antibodies was performed using the Abbott SARS-CoV-2 IgG quantitative assay (Abbott). Overall, mean titer of anti-Spike antibodies was 19,319.2 ± 1787.5 AU/mL. Vaccination induced a robust immunogenic response in those previously infected with SARS-CoV-2 compared with non-infected subjects. Additionally, individuals that were asymptomatic after vaccination produced lower levels of antibodies compared to feverish individuals. In conclusion, remarkably high levels of anti-Spike COVID-19 antibodies were observed after vaccination.

Article activity feed

  1. Version published to 10.3390/jcm10132842
  2. ScreenIT

    SciScore for 10.1101/2021.04.05.21254934: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    IgG Testing: The measurement of anti-Covid-19 antibodies was performed using the Abbott Architect i1000SR instrument (Abbott Diagnostics, IL, USA) using the Abbott SARS-CoV-2 IgG quantitative kit and following manufacturer’s instructions.
    anti-Covid-19
    suggested: None
    Software and Algorithms
    SentencesResources
    IgG Testing: The measurement of anti-Covid-19 antibodies was performed using the Abbott Architect i1000SR instrument (Abbott Diagnostics, IL, USA) using the Abbott SARS-CoV-2 IgG quantitative kit and following manufacturer’s instructions.
    Abbott Architect
    suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    A limitations of the study is the relatively small group of vaccinated patients after SARS CoV infection.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.04.05.21254934 on medRxiv